3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Leukemia, Myeloid, Acute
245
Precursor Cell Lymphoblastic Leukemia-Lymphoma
143
Myelodysplastic Syndromes
142
Leukemia, Lymphocytic, Chronic, B-Cell
139
Leukemia
127
Multiple Myeloma
117
Lymphoma
115
Lymphoma, Non-Hodgkin
112
Recurrence
79
Hematologic Neoplasms
74
Melanoma
68
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
67
Hodgkin Disease
67
Lymphoma, B-Cell
61
Lymphoma, Mantle-Cell
51
Lymphoma, Large B-Cell, Diffuse
50
Lymphoma, Follicular
50
Burkitt Lymphoma
41
Ovarian Neoplasms
40
Neoplasms
39
Myeloproliferative Disorders
39
Neoplasm Metastasis
34
Lymphoma, B-Cell, Marginal Zone
30
Graft vs Host Disease
29
Neoplasms, Plasma Cell
28
Carcinoma, Non-Small-Cell Lung
27
Breast Neoplasms
27
Leukemia, Biphenotypic, Acute
25
Primary Myelofibrosis
24
Anemia, Refractory, with Excess of Blasts
23
Interventions
Nivolumab
14
Ipilimumab
11
Specimen Handling
9
CTLA-4 Antigen
7
pembrolizumab
6
cabozantinib
6
Magnetic Resonance Spectroscopy
6
Sunitinib
5
Axitinib
5
pazopanib
4
Biopsy
4
Radiosurgery
3
lenvatinib
2
fludarabine
2
Everolimus
2
tivozanib
1
sodium-iodide symporter
1
sitravatinib
1
belzutifan
1
atezolizumab
1
aldesleukin
1
Zoledronic Acid
1
Selenomethionine
1
Radiotherapy
1
Radiopharmaceuticals
1
Pluvicto
1
Nephrectomy
1
Metastasectomy
1
LY2510924
1
Inulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Clear-cell metastatic renal cell carcinoma
×
fludarabine
×
Clear all
NCT07551349
2026-04-24
DUAL-NK RCC
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled
NCT04696731
2025-09-25
TRAVERSE
Allogene Therapeutics
Phase 1
Active not recruiting
120 enrolled